help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donaldson, C. J.
Right arrow Articles by Vale, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donaldson, C. J.
Right arrow Articles by Vale, W. W.
Endocrinology Vol. 140, No. 4 1760-1766
Copyright © 1999 by The Endocrine Society

ARTICLES

Activin and Inhibin Binding to the Soluble Extracellular Domain of Activin Receptor II1

Cynthia J. Donaldson, Joan M. Vaughan, Anne Z. Corrigan, Wolfgang H. Fischer and Wylie W. Vale2

The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037

Address all correspondence and requests for reprints to: Wylie Vale, Ph.D., The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, California 92037. E-mail: vale{at}salk.edu

Activins and inhibins belong to the transforming growth factor-ß-like superfamily of growth and differentiation factors that exert pleiotropic effects in many target tissues. Heteromeric association of activin with two structurally related receptor serine/threonine kinases, activin receptor types I and II, initiates downstream signaling events. The extracellular domain of type II mouse activin receptor (ActRII ECD) was expressed in the baculovirus system, purified in three steps by lectin affinity, anion exchange, and reverse phase chromatography, and further characterized by mass spectrometry. The reduction in the apparent size of the purified ActRII ECD on SDS-PAGE after treatment with glycosidases provided evidence for N- and O-linked oligosaccharides. Specific receptor/ligand complexes of [125I]activin A to ActRII ECD or [125I]ActRII ECD to activin A were analyzed by cross-linking and immunoprecipitation. Two major radiolabeled bands were observed on SDS-PAGE with mobilities consistent with the expected size of ActRII ECD/ßA or ActRII ECD/ßAßA. When inhibin A was cross-linked to [125I]ActRII ECD, a slower migrating complex corresponding to ActRII ECD/ßA{alpha} was also observed. The apparent dissociation constant (Kd) for activin A binding to ActRII ECD was 2–7 nM. This Kd value is approximately an order of magnitude greater than that of the full-length membrane-associated type II receptor. Treatment of cultured rat anterior pituitary cells with ActRII ECD attenuated FSH secretion in response to exogenous activin A or endogenous activin B. These data indicate that the soluble ActRII ECD has structural determinants that are sufficient for high affinity ligand binding.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
R. S. Pearsall, E. Canalis, M. Cornwall-Brady, K. W. Underwood, B. Haigis, J. Ucran, R. Kumar, E. Pobre, A. Grinberg, E. D. Werner, et al.
A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
PNAS, May 13, 2008; 105(19): 7082 - 7087.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein
Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. del Re, Y. Sidis, D. A. Fabrizio, H. Y. Lin, and A. Schneyer
Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System
J. Biol. Chem., December 17, 2004; 279(51): 53126 - 53135.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. M. O. Leal, K. Takabe, L. Wang, C. J. Donaldson, L. A. MacConell, L. M. Bilezikjian, I. M. Verma, and W. Vale
Effect of Adenovirus-Mediated Overexpression of Follistatin and Extracellular Domain of Activin Receptor Type II on Gonadotropin Secretion in Vitro and in Vivo
Endocrinology, March 1, 2002; 143(3): 964 - 969.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. C. Gray, J. Greenwald, A. L. Blount, K. S. Kunitake, C. J. Donaldson, S. Choe, and W. Vale
Identification of a Binding Site on the Type II Activin Receptor for Activin and Inhibin
J. Biol. Chem., February 4, 2000; 275(5): 3206 - 3212.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society